Dr. Fenstermaker earned his medical degree at the Northeast Ohio Medical University and did his residency training in neurosurgery at University Hospitals of Cleveland. He then served as a NIH Post-doctoral Fellow in Pharmacology and Biochemistry at Case Western Reserve University School of Medicine and was a member of the neurosurgical faculty at CWRU from 1989 through 1994. In 1995, he joined the faculty of the University at Buffalo School of Medicine and Biomedical Sciences where he has headed the neurosurgery service at Roswell Park Cancer Institute. Dr. Fenstermaker specializes in the neurosurgical treatment of patients with tumors of the brain, skull base and pituitary gland. His practice includes stereotactic and MRI-based cranial surgery for primary and metastatic brain tumors, as well as open and endoscopic skull base surgery and Gamma Knife radiosurgery. His research focuses on the study of immunotherapy for the treatment of malignant primary brain tumors. He is a member of the CNS Tumor Guidelines Panel of the National Comprehensive Cancer Network and is the co-founder of MimiVax, LLC, located in Buffalo, New York.